相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Persistent Diffusion-Restricted Lesions in Bevacizumab-Treated Malignant Gliomas Are Associated with Improved Survival Compared with Matched Controls
S. Mong et al.
AMERICAN JOURNAL OF NEURORADIOLOGY (2012)
Cancer Statistics, 2012
Rebecca Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2012)
New prognostic factors and calculators for outcome prediction in patients with recurrent glioblastoma: A pooled analysis of EORTC Brain Tumour Group phase I and II clinical trials
Thierry Gorlia et al.
EUROPEAN JOURNAL OF CANCER (2012)
Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study
Whitney B. Pope et al.
JOURNAL OF NEURO-ONCOLOGY (2012)
Response assessment in recurrent glioblastoma treated with irinotecan-bevacizumab: comparative analysis of the Macdonald, RECIST, RANO, and RECIST plus F criteria
Jaime Gallego Perez-Larraya et al.
NEURO-ONCOLOGY (2012)
Prediction of Glioblastoma Multiform Response to Bevacizumab Treatment Using Multi-Parametric MRI
Mohammad Najafi et al.
PLOS ONE (2012)
Advances in MRI Assessment of Gliomas and Response to Anti-VEGF Therapy
Whitney B. Pope et al.
CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS (2011)
Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumab
Michael Prados et al.
NEURO-ONCOLOGY (2011)
Diffusion Magnetic Resonance Imaging Detects Pathologically Confirmed, Nonenhancing Tumor Progression in a Patient With Recurrent Glioblastoma Receiving Bevacizumab
Elizabeth R. Gerstner et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group
Patrick Y. Wen et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Imaging response criteria for recurrent gliomas treated with bevacizumab: Role of diffusion weighted imaging as an imaging biomarker
Rajan Jain et al.
JOURNAL OF NEURO-ONCOLOGY (2010)
Bevacizumab-induced diffusion-restricted lesions in malignant glioma patients
Johannes Rieger et al.
JOURNAL OF NEURO-ONCOLOGY (2010)
Glioblastoma: A Method for Predicting Response to Antiangiogenic Chemotherapy by Using MR Perfusion Imaging-Pilot Study
Rahul N. Sawlani et al.
RADIOLOGY (2010)
Edema Control by Cediranib, a Vascular Endothelial Growth Factor Receptor-Targeted Kinase Inhibitor, Prolongs Survival Despite Persistent Brain Tumor Growth in Mice
Walid S. Kamoun et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
Henry S. Friedman et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma
Teri N. Kreisl et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Relationship of pre-surgery metabolic and physiological MR imaging parameters to survival for patients with untreated GBM
Forrest W. Crawford et al.
JOURNAL OF NEURO-ONCOLOGY (2009)
Evaluation of MR markers that predict survival in patients with newly diagnosed GBM prior to adjuvant therapy
Suja Saraswathy et al.
JOURNAL OF NEURO-ONCOLOGY (2009)
Recurrent Glioblastoma Multiforme: ADC Histogram Analysis Predicts Response to Bevacizumab Treatment
Whitney B. Pope et al.
RADIOLOGY (2009)
Grading Astrocytic Tumors by Using Apparent Diffusion Coefficient Parameters: Superiority of a One- versus Two-Parameter Pilot Method
Ryuji Murakami et al.
RADIOLOGY (2009)
Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan
Sith Sathornsumetee et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Bevacizumab for recurrent malignant gliomas - Efficacy, toxicity, and patterns of recurrence
A. D. Norden et al.
NEUROLOGY (2008)
Iatrogenic immunosuppression in patients with newly diagnosed high-grade gliomas
S. A. Grossman et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Prognostic factors for survival in adult patients with recurrent glioma enrolled onto the new approaches to brain tumor therapy CNS consortium phase I and II clinical trials
Kathryn A. Carson et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients
Tracy T. Batchelor et al.
CANCER CELL (2007)
Malignant astrocytic tumors: Clinical importance of apparent diffusion coefficient in prediction of grade and prognosis
Shuichi Higano et al.
RADIOLOGY (2006)
MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy
WB Pope et al.
NEUROLOGY (2006)
Minimum apparent diffusion coefficients in the evaluation of brain tumors
O Kitis et al.
EUROPEAN JOURNAL OF RADIOLOGY (2005)
Apparent diffusion coefficient of human brain tumors at MR imaging
F Yamasaki et al.
RADIOLOGY (2005)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R Stupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Lymphomas and high-grade astrocytomas: Comparison of water diffusibility and histologic characteristics
AC Guo et al.
RADIOLOGY (2002)
分享论文
